• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Risperdal Consta (risperidone) long-acting injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2010

Summary View


Other Adverse Reactions Observed During the Premarketing Evaluation of Risperdal Consta
  • abdominal pain upper, respiratory tract infection, glucose urine present, initial insomnia, ejaculation delayed, pruitus generalized
Postmarketing Experience
  • urinary retention, diabetes mellitus and hypoglycemia